PCN106 Cost-Minimization and Budget Impact Analysis of Venetoclax plus Obinutuzumab Versus Ibrutinib in Patients with Untreated Chronic Lymphocytic Leukemia in the Brazilian Private Healthcare System
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.198
https://www.valueinhealthjournal.com/article/S1098-3015(21)00415-0/fulltext
Title :
PCN106 Cost-Minimization and Budget Impact Analysis of Venetoclax plus Obinutuzumab Versus Ibrutinib in Patients with Untreated Chronic Lymphocytic Leukemia in the Brazilian Private Healthcare System
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00415-0&doi=10.1016/j.jval.2021.04.198
First page :
Section Title :
Open access? :
No
Section Order :
10773